Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis. T…
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.